Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer

Journal of Clinical Oncology

Volumn 21, Issue 15, 2003, Pages 2926-2932

  Ilson, David H ^a   Bains, Manjit ^a   Kelsen, David P ^a   O'Reilly, Eileen ^a   Karpeh, Martin ^a   Coit, Daniel ^a   Rusch, Valerie ^a   Gonen, Mithat ^a   Wilson, Katie ^a   Minsky, Bruce D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DYSPHAGIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; HUMAN; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; TUBE FEEDING; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ESOPHAGUS TUMOR; FEMALE; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, ADENOSQUAMOUS; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0042887575     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.02.147     Document Type: Article

References (32)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
2. Walsh TN, Noonan N, Hollywood D, et al: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462-467, 1996
3. Kelsen DP, Ginsberg R, Pajak T, et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1979-1984, 1998
4. Cooper J, Guo M, Herskovic A et al: Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 281:1623-1627, 1999
5. Urba SG, Orringer MB, Turrisi A, et al: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305-313, 2001
6. Lin L, Hecht J, et al: A phase ii trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal (GE) junction. Proc Am Soc Clin Oncol 19:289a, 2000 (abstr 1130)
7. Enzinger P, Kulke M, Clark J, et al: Phase II trial of CPT-11 in previously untreated patients with advanced adenocarcinoma of the esophagus and stomach. Proc Am Soc Clin Oncol 19:315a, 2000 (abstr 1243)
8. Ilson DH, Saltz L, Enzinger P, et al: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17:3270-3275, 1999
9. Ajani J, Baker J, Pisters P, et al: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a phase II study. Cancer 94:641-646, 2002
10. Okishio K, Kudoh S, Kurihara N, et al: Irinotecan (CPT-11) enhances the radiosensitivity of lung cancer in vitro. Proc Am Soc Clin One 14:362, 1995 (abstr 1109)
11. Watanabe A, Nishiwaki K, Hasegawa Y, et al: Effects of Taxotere (docetaxel) and of irinotecan (CPT-11) combined with radiation on lung cancer cell lines. Proc Am Soc Clin Oncol 14:494, 1995 (abstr 1617)
12. Tamura K, Takada M, Kawase I, et al: Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res 88:218-223, 1997
13. Szumiel I, Buraczewska I, Gradzka I, et al: Effects of topoisomerase I-targeted drugs on radiation response of L5178Y sublines differentially radiation and drug sensitive. Int J Radiat Biol 67:441-448, 1995
14. Chen AY, Okunieff P, Pommier Y, et al: Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res 57:1529-1536, 1997
15. Kudoh S, Kurihara N, Okishio K, et al: A phase I-II study of weekly irinotecan (CPT-11) and simultaneous thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin One 15:372, 1996 (abstr 1102)
16. Saka H, Shimokata S, Yoshida K, et al: Irinotecan (CPT-11) and concurrent radiotherapy in locally advanced non-small cell lung cancer (NSCLC): A phase II study of Japan Clinical Oncology Group (JCOG 9504). Proc Am Soc Clin Oncol 16:502, 1997 (abstr 1607)
17. Knyrim K, Wagner HJ, Bethge N, et al: A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med 329:1302-1307, 1993
18. Minsky BD, Pajak TF, Ginsberg RJ, et al: INT 123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167-1174, 2002
19. Ilson DH, Forastiere A, Arquette M, et al: A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 6:316-323, 2000
20. Petrasch S, Welt A, Reinacher A, et al: Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 78:511-514, 1998
21. van der Gaast A, Kok TC, Kerkhofs L, et al: Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer. Br J Cancer 80:1052-1057, 1999
22. Bains M, Stojadinovic A, Minsky B, et al: A phase II trial of preoperative combined modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiovasc Surg 124:270-277, 2002
23. Safran H, Gaissert H, Akerman P, et al: Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 19:1-7, 2001
24. Wright CD, Wain JC, Lynch TJ, et al: Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: A phase I and II study. J Thorac Cardiovasc Surg 114:811-815, 1997
25. Meluch AA, Hainsworth JD, Gray JR, et al: Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: Preliminary results of a Minnie Pearl Cancer Res Network phase II trial. Cancer J Sci Am 5:84-91, 1999
26. Adelstein D, Rice TW, Rybicki LA, et al: Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A non-randomized comparison with fluorouracil-based therapy. J Clin Oncol 18:2032-2039, 2000
27. Bates BA, Detterbeck FC, Bernard SA, et al: Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 14:156-163, 1996
28. Heath EI, Burtness BA, Heitmiller RF, et al: Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 18:868-876, 2000
29. Stahl M, Wilke H, Fink U, et al: Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer: Interim analysis of a phase II trial. J Clin Oncol 14:829-837, 1996
30. Ajani JA, Komaki R, Putnam JB, et al: A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92:279-286, 2001
31. Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001
32. Saltz L, Cox J, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000